Disc Medicine Shares Fall After FDA Issues Complete Response Letter for EPP Drug
Disc Medicine Inc.'s stock tumbled after the U.S. Food and Drug Administration issued a Complete Response Letter for bitopertin, the company's investigational therapy for erythropoietic protoporphyria (EPP). The FDA said it requires results from the ongoing Phase 3 APOLLO study before it can rule on approval. Disc Medicine provided updated timing f…